|Jmol-3D images||Image 1|
|Molar mass||276.29 g mol−1|
|Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)|
SCH 900271 is a nicotinic acid derivative designed to treat dyslipidemia. It reduced plasma free fatty acids levels, but without significant flushing, a side effect common with niacin that limits its usefulness. SCH 900271 is currently in human trials.